Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Esomeprazol untuk esofagitis refluks erosif

Penilaian teknologi kesehatan PTK-A02BC05 Draf untuk telaah Diperbarui 15 Juni 2026

1. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Esomeprazol 40 mg sekali sehariRp 20,3 juta7,1109,48
omeprazol 20 mg sekali sehariRp 11,7 juta7,0829,48
SelisihRp 8,6 juta0,029-

2. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
05101520250,000,020,040,060,08Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta30,1%

3. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-10-50510interventions esomeprazole 40mg OD annual drug cost idrinterventions esomeprazole 40mg OD...interventions omeprazole 20mg OD transition rate multipliers healed maintenance to symptomatic relapseinterventions omeprazole 20mg OD t...interventions omeprazole 20mg OD transition rate multipliers erosive uncontrolled to healed maintenanceinterventions omeprazole 20mg OD t...interventions esomeprazole 40mg OD transition rate multipliers healed maintenance to symptomatic relapseinterventions esomeprazole 40mg OD...interventions omeprazole 20mg OD annual drug cost idrinterventions omeprazole 20mg OD a...interventions esomeprazole 40mg OD transition rate multipliers erosive uncontrolled to healed maintenanceinterventions esomeprazole 40mg OD...interventions omeprazole 20mg OD transition rate multipliers symptomatic relapse to refractory complicatedinterventions omeprazole 20mg OD t...utility values erosive uncontrolledutility values erosive uncontrolle...utility values healed maintenanceutility values healed maintenanceinterventions esomeprazole 40mg OD transition rate multipliers symptomatic relapse to refractory complicatedinterventions esomeprazole 40mg OD...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

4. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (10 yr)0,029Rp 8,6 jutaRp 301,1 juta
5-year horizon0,018Rp 4,6 jutaRp 260,1 juta
0% discount rate0,033Rp 10,1 jutaRp 305,7 juta
5% discount rate0,026Rp 7,8 jutaRp 298,3 juta
Generic esomeprazole near price parity with omeprazole (esomeprazole annual cost set to ~Rp 300k)0,029-Rp 26.440Lebih efektif dan lebih hemat
Branded Nexium acquisition price (esomeprazole annual cost ~Rp 4.38m, builder B figure)0,029Rp 34,8 jutaRp 1,2 miliar
Upper-bound healing advantage per pivotal trials (~9.5% absolute; healing multiplier x1.14, relapse x0.80)0,049Rp 8,3 jutaRp 171,7 juta
Small esomeprazole AE excess from greater acid suppression (complication multiplier x1.10; sensitivity only)0,025Rp 8,9 jutaRp 360,4 juta

5. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).

Luaran pembandingPrediksi modelData terbitSumber
Erosive-oesophagitis healing into maintenance (omeprazole 20 mg arm), annual transition proxy for ~84-90% week-8 healing82,0%86,0%Omeprazole 20 mg week-8 erosive-oesophagitis healing 84-90% (Kahrilas 2000 84.2%; Castell 2002 84.2%).
Annual symptomatic relapse from healed maintenance (omeprazole arm)20,0%20,0%Relapse on maintenance PPI ~15-25%/yr in long-term erosive-oesophagitis maintenance studies (Labenz 1997; DeVault & Cast
All-cause mortality at 10 yr (GERD cohort age 50, comparator)10,4%12,0%Approximate 10-yr all-cause mortality for an Indonesian 50-year-old cohort (WHO life tables / Riskesdas); GERD itself is

6. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • Threshold: WHO-CHOICE proxy 1x PDB Rp 75jt/QALY; 3x PDB Rp 225jt/QALY; InaHTAC may apply different decision rules.
  • Both esomeprazole and omeprazole are BPOM-registered and available in Indonesia; omeprazole is the generic Fornas/JKN backbone PPI, while esomeprazole (Nexium and generics such as Esomeprazole Etercon) is marketed at a substantial price premium.
  • NICE CG184's lowest-acquisition-cost-PPI recommendation maps directly onto an Indonesian Fornas stewardship stance: omeprazole first-line, esomeprazole reserved for persistent/severe (LA C/D) disease.
  • The base-case result is dominated by the esomeprazole-minus-omeprazole price gap; the price-parity scenario is the single most decision-relevant analysis and is included in scenario_config alongside a branded-price scenario.
  • Budget impact is driven almost entirely by drug-acquisition difference because healing and complication differences are marginal; even modest penetration of a premium PPI in a high-prevalence condition produces a large incremental JKN cost.
  • Reviewers should verify current Fornas listing/restriction status for esomeprazole and obtain validated INAPROC/e-katalog LKPP unit prices before any policy interpretation.